Atara Biotherapeutics
ATRA
41 hedge funds and large institutions have $37.1M invested in Atara Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
37% more capital invested
Capital invested by funds: $27M → $37.1M (+$10.1M)
11% more funds holding
Funds holding: 37 → 41 (+4)
1.61% more ownership
Funds ownership: 26.81% → 28.43% (+1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Globeflex Capital
San Diego,
California
|
+$922K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$490K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$336K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$279K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$273K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$376K |
| 2 |
Morgan Stanley
New York
|
-$298K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$237K |
| 4 |
Jane Street
New York
|
-$120K |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$76.8K |
ATRA Hedge Fund Activity: Q4 2025 in Review
41 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2025, worth a combined $37.1M — up 37% from $27M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ATRA positions and 3 closed out — a net gain of 4 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Globeflex Capital, adding an estimated $922K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $376K sold.
- 41 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2025, up from 37 in Q3 2025.
- Funds reported $37.1M of Atara Biotherapeutics stock for Q4 2025, up 37% quarter-over-quarter.
- 7 funds opened new Atara Biotherapeutics positions in Q4 2025 and 3 closed out, a net change of +4 holders.
- The largest Atara Biotherapeutics buyer in Q4 2025 was Globeflex Capital, an estimated $922K added.
- The largest Atara Biotherapeutics seller in Q4 2025 was GSA Capital Partners, an estimated $376K sold.
Based on aggregated 13F filings for Q4 2025.